ClinicalTrials.gg
Status unknownNCT04994223Updated May 3, 2022

Effectiveness of Combined Anticoagulation and Antithrombotic Therapy vs Antithrombotic Therapy Alone After Lower Extremity Revascularization for Peripheral Arterial Disease

An Early Phase 1 interventional study of Rivaroxaban 10 MG Oral Tablet [Xarelto] in Combined Anticoagulation and Antithrombotic Therapy and PAD - Peripheral Arterial Disease, sponsored by Armed Forces Post Graduate Medical Institute (AFPGMI), Rawalpindi. Status unknown at 1 site in Pakistan. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-03.

Sponsored by Armed Forces Post Graduate Medical Institute (AFPGMI), Rawalpindi · Early Phase 1, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Apr 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies testing rivaroxaban in Peripheral Arterial Disease — 3 open to participants now, 3 under way, none of them phase 3. Rivaroxaban · Peripheral Arterial Disease.

Planned enrollment
11th of 13
60 · median 100
Started
2021
with 2 others
Phase 1
2 of 13
none open now
Registered
8th of 13
by date
Lead sponsor
1 of 13
Armed Forces Post Graduate Medical Institute (AFPGMI), Rawalpindi

Among the 13 studies testing rivaroxaban in Peripheral Arterial Disease, this one is the 11th largest by planned enrollment, is one of 3 that started in 2021, is one of 2 in phase 1, and was the 8th registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

3 of the 13 studies testing rivaroxaban in Peripheral Arterial Disease are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About rivaroxaban

Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing rivaroxaban in Peripheral Arterial Disease, or all of them as a file.
02

Study summary

EFFECTIVENESS OF COMBINED ANTICOAGULATION AND ANTITHROMBOTIC THERAPY VS ANTITHROMBOTIC THERAPY ALONE AFTER LOWER EXTREMITY REVASCULARIZATION FOR PERIPHERAL ARTERIAL DISEASE.

Read the detailed description

Anticoagulation and antithrombotic therapy is a crucial part of PAD management as it prolongs the patecy of grafts in open surgical revascularization procedures so its proper dosage and duration without increasing risks to the patient and maximizing the benefits is very important.

Currently literature in Pakistan regarding this problem couldn't be found so this study would help assessing the outcomes of anticoagulation and antithrombotic therapy in this population with respect to treatment options available and presentation variability of the peripheral arterial disease. Patients with PAD would be enrolled for 6 months and would be followed upto 12 months and then upto 24 months.

Eligible subjects will be randomized 1:1 to receive either rivaroxaban 5 mg twice daily plus aspirin 75 mg once daily or rivaroxaban-matching placebo twice daily plus aspirin 75 mg once daily stratified by type of procedure; the treatment assignment will be double-blinded. Randomization and study treatment will begin as soon as possible but no later than 10 days after a successfull lower extremity revascularization.

Patients will be prohibited from taking any additional antithrombotic therapy other drugs, including anticoagulants, doses of aspirin >100 mg daily, vorapaxar, ticagrelor, prasugrel, or cilostazol. Enrolled subjects will be having symptomatic PAD defined by evidence of an abnormal ankle-brachial index ≤0.80 in either limb with an anatomy of occlusive disease of involving segments. Subjects would be randomized who had undergone a technically successful endovascular, hybrid, or surgical LER within 10 days and had achieved adequate hemostasis before randomization.

03

Conditions studied

  • Combined Anticoagulation and Antithrombotic Therapy
  • PAD - Peripheral Arterial Disease

Keywords

  • rivaroxaban in PAD
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • all patients with PAD candidates for revascularization procedures

Exclusion criteria

Exclusion Criteria:

  1. planned long-term dual antiplatelet therapy (>6 months),
  2. clinical requirement for therapeutic anticoagulation,
  3. recent acute limb ischemia or acute coronary syndrome,
  4. medical condition that could increase the risk of major bleeding, significantly impaired renal function at baseline (estimated \<15 mL•min-1•1.73 m-2),
  5. any documented history of intracranial hemorrhage, stroke, or
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Group A(combined anticoagulation plus antithrombotic therapy group)

    group A patients would be receiving rivaroxaban and aspirin as experimental group to see the efficacy of rivaroxaban in peripheral arterial disease.

    Drug: Rivaroxaban 10 MG Oral Tablet [Xarelto]

  • Active comparator
    Group B( antithrombotic therapy alone group)

    group B patients would be those receiving traditional antithrombotic therapy as usually given n Peripheral Arterial Disease.

    Drug: Rivaroxaban 10 MG Oral Tablet [Xarelto]

Interventions

  • DrugRivaroxabanStudies of RivaroxabanRivaroxaban pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    rivaroxaban has shown improved results after revascularization for PAD in terms of limb survival

06

What researchers measure

Primary outcomes

  1. ALI

    acute limb ischemia

    Time frame: upto 1 year

  2. major amputation for vascular reasons

    any type of major amputation after revascularivation for PAD

    Time frame: upto 1 year

  3. MI

    myocardial infarction

    Time frame: upto 1 year

  4. ischemic stroke

    ischemic stroke

    Time frame: upto 1 year

  5. cardiovascular death

    death because of cardiovascular events

    Time frame: upto 1 year

Secondary outcomes

  1. thrombolysis in myocardial infarction(TIMI)major bleeding

    combined therapy effect may result in increased bleeding tendency

    Time frame: 2, 30, 180 and 365 days

07

Study locations

1 of 1 sites recruiting
  • Combined Military Hospital
    Rawalpindi, Punjab 46000, Pakistan
    Recruiting
    • muhammad jamil, MBBS, FCPS General Surgery · Contact+923216409020
    • muhammad irfan, MBBS,FCPS Surgery · Contactirfan1373@yahoo.com · +923339259643
08

References and documents

Individual participant data

Plan to share: Yes — title

Supporting information: Study protocol

Time frame: 6 months from start of study

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2021 (actual). Primary completion is estimated for Dec 2022, 17 months after the start.

Of 26 phase 1 interventional studies under Peripheral Arterial Disease, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's planned 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2021
First posted
Aug 6, 2021
StartActual
Jul 2, 2021
Primary completionEst.
Dec 30, 2022
CompletionEst.
Dec 30, 2022
Last update
May 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04994223
Lead sponsor
Armed Forces Post Graduate Medical Institute (AFPGMI), Rawalpindi
Responsible party
Ayesha Masood (Trainee in vascular surgery, Armed Forces Post Graduate Medical Institute (AFPGMI), Rawalpindi) — Principal investigator
First posted
Aug 6, 2021
Start date
Jul 2, 2021
Primary completion
Dec 30, 2022 (estimated)
Completion
Dec 30, 2022 (estimated)
Last update
May 3, 2022

Study contacts

Ayesha masood, MBBS, FCPS Surgery
Contact
laparoscopy.6@gmail.com
+923059159699
Muhammad Irfan, MBBS,FCPS Surgery,
Contact
irfan1373@yahoo.com
+923339259643

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion